News stories about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vital Therapies earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.35942209826 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several research analysts have weighed in on the stock. Raymond James Financial, Inc. assumed coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They issued an “outperform” rating and a $6.00 price objective on the stock. ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Vital Therapies (VTL) opened at 3.875 on Wednesday. The firm has a 50-day moving average of $2.90 and a 200 day moving average of $3.36. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.58. The firm’s market cap is $163.55 million.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. During the same quarter in the prior year, the business posted ($0.30) earnings per share. Analysts expect that Vital Therapies will post ($1.31) earnings per share for the current fiscal year.

In related news, Director Muneer A. Satter purchased 50,000 shares of the business’s stock in a transaction on Friday, September 8th. The shares were purchased at an average price of $3.53 per share, with a total value of $176,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 32.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Vital Therapies (VTL) Stock Price” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with's FREE daily email newsletter.